Martin Edelman, MD

Articles by Martin Edelman, MD

Lung Cancer in the Elderly: Factors to Consider

ByStuart M. Lichtman, MD, FACP,Martin Edelman, MD

November 1st 2007

The issue of cancer in the elderly is of growing concern given the aging population. It is a particular issue in lung cancer, where the median age of patients is over 60.

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

ByDavid R. Gandara, MD,Martin Edelman, MD,Primo N. Lara, Jr, MD,Derick H. M. Lau, MD, PhD,Peter Roberts, MD,Bryan R. Leigh, MD

July 2nd 2000

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung

Latest Updated Articles

Lung Cancer in the Elderly: Factors to Consider
November 1st 2007
Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
July 2nd 2000

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)